Dynavax Technologies Corporation (DVAX)

Market Cap	1.65B
Revenue (ttm)	277.25M
Net Income (ttm)	27.31M
Shares Out	124.07M
EPS (ttm)	0.20
PE Ratio	66.65
Forward PE	40.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,822,614
Open	13.83
Previous Close	13.33
Day's Range	13.29 - 14.05
52-Week Range	9.74 - 14.05
Beta	1.32
Analysts	Hold
Price Target	25.33 (+90.02%)
Earnings Date	Feb 20, 2025

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 19, 2004
• Employees: 408
• Stock Exchange: NASDAQ
• Ticker Symbol: DVAX
• Website: https://www.dynavax.com

Analyst Forecast

According to 3 analysts, the average rating for DVAX stock is "Hold." The 12-month stock price forecast is $25.33, which is an increase of 90.02% from the latest price.

Price Target

$25.33

(90.02% upside)

Analyst Consensus: Hold